Pere Santamaria

Company: Parvus Therapeutics

Job title: Chief Scientific Officer

Seminars:

Harnessing Peptide-Major Histocompatibility Complex- Based Nanomedicines to Treat Autoimmunity by Expanding Antigen-Specific Tregs In Vivo 1:00 pm

Analyzing nanomedicines as effective triggers of endogenous Treg generation to modulate immunoregulation Describing the mechanisms of action involved in the pMHC nanomedicine platform to generate disease specific Tregs Exploring applications of pMHC nanomedicines in Liver autoimmunity, T1D and MSRead more

day: Day 1 Treg Modulatorstrack